Form 4: Enliven CSO Sells 12,500 Shares Under 10b5-1 Plan
Insider Transaction Report
Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 12,500 shares of common stock on November 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported the sale of 12,500 shares of common stock.
- The transactions occurred on November 19, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
- One block of 12,008 shares was sold at a weighted average price of $22.3013 per share.
- Another block of 492 shares was sold at a weighted average price of $23.091 per share.
- Following these transactions, Lyssikatos beneficially owns 902,688 shares, held indirectly through The Lyssikatos Revocable Trust 12/15/2011.
Sentiment
Score: 4
Explanation: The sale of shares by a Chief Scientific Officer, even under a pre-arranged 10b5-1 plan, can be interpreted as a slight negative signal regarding the insider's personal financial strategy or diversification needs, rather than a direct reflection of company performance.
Positives
- The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating the transactions were not based on new, non-public information.
Negatives
- A significant sale of 12,500 shares by a Chief Scientific Officer could be perceived negatively by investors, potentially signaling a desire for diversification or personal financial planning rather than a direct reflection of company performance.
Future Outlook
No specific future outlook or guidance is provided in this insider transaction report.
Industry Context
This insider transaction is a routine disclosure for publicly traded companies across all industries. It reflects an individual executive's personal financial planning rather than a specific industry trend or competitive development for Enliven Therapeutics.
Related Party Transactions
- The shares are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which the Reporting Person serves as trustee.
Stakeholder Impact
- Shareholders may view the insider sale as a slight negative signal, potentially impacting investor sentiment, though the pre-arranged 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2011-12-15 | Establishment date of The Lyssikatos Revocable Trust, which indirectly holds the shares. |
| 2024-11-15 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-11-19 | Date of the reported stock transactions (sales of common stock). |
| 2025-11-21 | Date the Form 4 was signed by power of attorney. |
Recommendation
holdThe sale by the Chief Scientific Officer, Joseph P. Lyssikatos, was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the transaction was for personal financial planning rather than a reaction to new, material non-public information. While insider selling can sometimes be a negative signal, the pre-planned nature and the relatively small percentage of total holdings sold (12,500 out of 903,180 shares beneficially owned before the transaction) do not warrant a change in investment thesis based solely on this filing. Investors should continue to hold and monitor company fundamentals and broader market conditions.
Keywords
Enliven Therapeutics, ELVN, Joseph P. Lyssikatos, Insider Trading, Form 4, Stock Sale, Chief Scientific Officer, 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.